Cell low-temperature preserving fluid as well as preparation method and application thereof
By preparing a cryopreservation solution for cells containing trehalose and L-ascorbic acid-2-magnesium phosphate, the activity of long-term preservation and transportation of cells in cell therapy was solved, and efficient cell protection was achieved under 2-8°C. Reduce shipping costs and simplify operations, suitable for a variety of cell types.
Patent Information
- Application Number
- CN202411167415.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-26
AI Technical Summary
The long-term storage and transportation of cells during cell treatment have a great impact on their activity. The existing technology has high-cost dry ice transportation, complex frozen storage and recovery processes and potential pollution risks, and the room-temperature storage solution cannot meet the long-term transportation needs.
Cell cryopreservation solution using sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, trehalose, L-ascorbic acid-2-magnesium phosphate and hydrocortisone, by preparing a specific concentration of solution, it provides 2 Cell protection at -8°C conditions avoids the toxicity of the freeze-thaw process and ensures cell activity.
Significantly reduces transportation costs, simplifies the operation process, ensures more than 92% of the cell's activity within 120 hours, is suitable for a variety of cell types, avoids the problems caused by heterogeneous proteins and biologically active molecules in frozen storage solution, and provides A safe and compatible storage environment.
Smart Images

Figure CN119014397A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of cell protection, and specifically relates to a cell cryopreservation solution and a preparation method and application thereof. Background Art
[0002] Cell therapy is a cutting-edge medical technology that involves the introduction of living cells into patients to treat various diseases. In the process of cell therapy, the preservation and transportation of cells is one of the key links. However, the long-term preservation and transportation of cells have a great impact on their activity, which has always been a technical problem. Currently, cells are usually stored in liquid nitrogen at -196°C to ensure their long-term activity. In practical applications, cells are usually transported by dry ice from the storage site to the site of use to maintain the low temperature environment of the cells. However, this mode of transportation has several significant disadvantages: First, the cost of dry ice transportation is high, especially when long-distance and international transportation is involved. Second, before cell therapy, frozen cells need to be resuscitated, which increases the complexity of the operation. In addition, traditional cell freezing solutions contain components such as DMSO (dimethyl sulfoxide) and serum, which may carry foreign proteins or uncertain bioactive molecules. They need to be cleaned and removed before use, which increases the operation steps and requirements for equipment and sites. These open operations require professional technicians to perform, are complicated to operate, and are prone to introduce contamination risks. These problems limit the widespread application of cell therapy, especially in areas or conditions with incomplete operating facilities. The new cryopreservation method uses low-toxic or non-toxic cryopreservation fluids, such as sugars or other chemicals that replace DMSO. This method reduces the recovery and washing steps to a certain extent, but it still needs to be stored and transported at extremely low temperatures. The room-temperature preservation fluid method develops a preservation fluid that can preserve cell activity at room temperature, usually using certain stabilizers or protective agents. This method simplifies the transportation process to a certain extent, but it can usually only maintain cell activity for a short period of time and cannot meet the needs of long-term transportation. For example: The cell preservation fluid currently on the market of a certain company is applicable to a limited number of cell types; the number of cells preserved is small, and the transportation conditions need to be controlled at -196°C for storage and transportation, which adds costs and poor cell activity after recovery; it is not conducive to the subsequent experimental operations. Summary of the invention
[0003] Purpose of the invention: The purpose of the present invention is to provide a cell cryopreservation solution, which can significantly improve the safety of cell transport in cell therapy, reduce costs, simplify the operating procedures, and thus have positive significance for the development and promotion of cell therapy.
[0004] Technical solution:
[0005] The formula of this invention uses sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, trehalose, L-ascorbic acid-2-phosphate magnesium salt, and hydrocortisone as main raw materials, and water as solvent; the mass concentration of each component is 7.5-8.5g / L of sodium chloride, 1.3-1.5g / L of disodium hydrogen phosphate, 480-500mg / L of sodium dihydrogen phosphate, 64-128mg / L of L-ascorbic acid-2-phosphate magnesium salt, 50-100g / L of trehalose and 350-520μg / L of hydrocortisone.
[0006] The formula contains trehalose and L-ascorbic acid-2-phosphate magnesium salt, of which trehalose is a typical stress metabolite formed by organisms in response to changes in the external environment, protecting the body from external harsh environments. At the same time, trehalose can also be used to protect DNA molecules in organisms from damage caused by radiation; exogenous trehalose also has a non-specific protective effect on organisms. Its protective mechanism is generally believed to be that the part of the body containing trehalose strongly binds water molecules, shares bound water with membrane lipids, or trehalose itself replaces membrane bound water, thereby preventing the denaturation of biological membranes and membrane proteins; and the high reducing ability of vitamins can protect cells from damage by oxidative free radicals. Ordinary ascorbic acid or vitamin C is very unstable at the optimal solution pH and temperature for cell growth. L-ascorbic acid-2-phosphate magnesium salt is a stable vitamin C derivative that can stimulate the expression and formation of collagen and is a better way to convert vitamin C. Due to its good stability, L-ascorbic acid-2-phosphate magnesium salt is a better choice.
[0007] Preferably, the mass concentration of each component is 8.0 g / L sodium chloride, 1.43 g / L disodium hydrogen phosphate, 500 mg / L sodium dihydrogen phosphate, 128 mg / L L-ascorbic acid-2-phosphate magnesium salt, 100 g / L trehalose and 370 μg / L hydrocortisone.
[0008] Preferably, the pH value of the cell preservation solution is between 6.8 and 7.2.
[0009] Preferably, the endotoxin in the cell storage medium is less than 0.5 EU / ml.
[0010] The present invention also provides a method for preparing a cell cryopreservation solution, characterized in that sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, trehalose, L-ascorbic acid-2-phosphate magnesium salt, and hydrocortisone are weighed as required, then added to 1L with pure water, and stirred evenly, and the solution is collected for filtration and sterilization; a portion of the sample is retained for appearance, pH value, endotoxin and preservation effect detection, and the appearance should be a transparent liquid without precipitation, suspended matter, flocculent matter, and no liquid leakage outside the bottle; the pH value should be between 6.8-7.2; the endotoxin is less than 0.5EU / ml; the cell preservation effect should be ≥92% within 120 hours; In the cell cryopreservation solution, the mass concentrations of the components are: sodium chloride 7.5-8.5 g / L, disodium hydrogen phosphate 1.3-1.5 g / L, sodium dihydrogen phosphate 480-500 mg / L, L-ascorbic acid-2-phosphate magnesium salt 64-128 mg / L, trehalose 50-100 g / L and hydrocortisone 350-520 μg / L.
[0011] The cell cryopreservation solution of the present invention can be used for the preservation of all cells, especially for the preservation of human umbilical cord mesenchymal stem cells, NK cells and K562 cells.
[0012] Beneficial effects:
[0013] The present invention improves the formula ingredients of the existing cell preservation solution, uses substances with clear chemical composition and permitted intravenous infusion in the pharmacopoeia, ensures safety and compatibility, and the appropriate pH and osmotic pressure can preserve cells in vitro for a short period of time and maintain their activity; The present invention is suitable for the storage and transportation of cells taken from the human body; it is free of dimethyl sulfoxide (DMSO), protein, and pyrogenic reaction; endotoxin is less than 0.5EU / ML; it can be transported at 2-8°C, reducing transportation costs and avoiding the use of high-cost dry ice transportation.
[0014] In liquid state and under low-temperature transportation conditions, it can provide the protective environment required by cells, ensure that the cells maintain good biological activity during experimental operations, avoid the toxicity of the freeze-thaw process to the cells, achieve cell activity of more than 92% within 5 days (120 hours), and smoothly carry out subsequent cell culture experiments and detection. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 This is the result of measuring the proliferation ability of cells by the cell preservation solution of the present invention. DETAILED DESCRIPTION
[0016] In order to deepen the understanding of the present invention, the present invention will be further described in detail below in conjunction with embodiments and drawings. The embodiments are only used to explain the present invention and do not constitute a limitation on the protection scope of the present invention.
[0017] The cells, raw materials, models and manufacturers used in this invention are shown in Table 1 below.
[0018] Table 1 Sources of cells and raw materials
[0019] Example 1 Preparation of cell cryopreservation solution Weigh sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, trehalose, L-ascorbic acid-2-phosphate magnesium salt, and hydrocortisone as required, then add pure water to 1L and stir evenly, collect the solution for filtration and sterilization; retain some samples for appearance, pH value, endotoxin and preservation effect testing, the appearance should be a transparent liquid, no precipitation, no suspended matter, no floccules, and no liquid leakage outside the bottle; the pH value should be between 6.8-7.2; endotoxin <0.5EU / ml; the cell preservation effect should be ≥92% within 120h; In the above-mentioned cell cryopreservation solution, the mass concentration of each component is 7.5g / L sodium chloride, 1.43g / L disodium hydrogen phosphate, 479.91mg / L sodium dihydrogen phosphate, 50g / L trehalose, 64mg / L L-ascorbic acid-2-phosphate magnesium salt, and 400μg / L hydrocortisone.
[0020] Example 2 Preparation of cell cryopreservation solution The difference from Example 1 is the mass concentration of each component, 7.2 g / L sodium chloride, 1.5 g / L disodium hydrogen phosphate, 500.0 mg / L sodium dihydrogen phosphate, 100 g / L trehalose, 128 mg / L L-ascorbic acid-2-phosphate magnesium salt, 350 μg / L hydrocortisone; Example 3 Preparation of cell cryopreservation solution The difference from Example 1 is the mass concentration of each component, 8.5 g / L sodium chloride, 1.35 g / L disodium hydrogen phosphate, 480.0 mg / L sodium dihydrogen phosphate, 50 g / L trehalose, 64 mg / L L-ascorbic acid-2-phosphate magnesium salt, 520 μg / L hydrocortisone; Example 4 Preparation of cell cryopreservation solution The difference from Example 1 is the mass concentration of each component, 8.0 g / L sodium chloride, 1.43 g / L disodium hydrogen phosphate, 500 mg / L sodium dihydrogen phosphate, 100 g / L trehalose, 128 mg / L L-ascorbic acid-2-phosphate magnesium salt, 370 μg / L hydrocortisone; Comparative Example 1 Cell preservation solution containing vitamin C The preparation method is the same as that of Example 1, except that L-ascorbic acid-2-phosphate magnesium salt is missing, and the concentrations of the other components are 7.5 g / L sodium chloride, 1.43 g / L disodium hydrogen phosphate, 479.91 mg / L sodium dihydrogen phosphate, 50 g / L trehalose, 64 mg / L vitamin C, and 400 μg / L hydrocortisone; Comparative Example 2 Cell preservation solution containing vitamin C The preparation method is the same as that of Example 1, except that L-ascorbic acid-2-phosphate magnesium salt is missing, and the concentrations of the other components are 7.2 g / L sodium chloride, 1.5 g / L disodium hydrogen phosphate, 500.0 mg / L sodium dihydrogen phosphate, 100 g / L trehalose, 128 mg / L vitamin C, and 350 μg / L hydrocortisone; Comparative Example 3 Cell preservation solution containing vitamin C The preparation method is the same as that of Example 1, except that L-ascorbic acid-2-phosphate magnesium salt is missing, and the concentrations of the other components are 8.5 g / L sodium chloride, 1.35 g / L disodium hydrogen phosphate, 480.0 mg / L sodium dihydrogen phosphate, 50 g / L trehalose, 64 mg / L vitamin C, and 520 μg / L hydrocortisone; Comparative Example 4 Cell preservation solution containing vitamin C The preparation method is the same as that of Example 1, except that L-ascorbic acid-2-phosphate magnesium salt is missing, and the concentrations of the other components are 8.0 g / L sodium chloride, 1.43 g / L disodium hydrogen phosphate, 500 mg / L sodium dihydrogen phosphate, 100 g / L trehalose, 128 mg / L vitamin C, and 370 μg / L hydrocortisone; Example 5: Survival rate of human umbilical cord mesenchymal stem cells Experimental steps: The collected human umbilical cord mesenchymal stem cells were centrifuged, the supernatant was removed, the cell pellet was resuspended, a portion of the cell suspension was taken and stained with trypan blue, and then the cell count was detected using a cell counter, and the cell viability at 0h was calculated; after determining the number of cells, the cell count was calculated according to 1*10 7 / ml, premixed with the cell preservation solution of Examples 1-4 and Comparative Examples 1-4; the cell activity was counted and detected at 24h, 48h, 72h, 96h, and 120h, and the cell viability was calculated; see Table 2 below Table 2. Human umbilical cord mesenchymal stem cell survival rate
[0021] The experimental results show that: in the cell preservation solution of Example 4 at 2-8°C, the activity of human mesenchymal stem cells is still maintained above 92% within 120 hours.
[0022] Example 6 NK cell survival rate The collected human NK cells were centrifuged, the supernatant was removed, the cell pellet was resuspended, and part of the cell suspension was taken for cell counting using a cell counter, and the cell viability at 0h was calculated; after the cell number was determined, the cell viability was calculated according to 1*10 7 / ml, premixed with the cell preservation solution of Examples 1-4 and Comparative Examples 1-4; the cell activities were counted and detected at 24h, 48h, 72h, 96h, and 120h, and the cell viability was calculated; Table 3 Human NK cell survival rate
[0023] The experimental results show that: in the cell preservation solution of Example 4, the activity of NK cells is still maintained above 92% within 120 hours at 2-8°C.
[0024] Example 7 K562 cell survival rate The collected K562 cells were centrifuged, the supernatant was removed, the cell pellet was resuspended, part of the cell suspension was taken, and the cell count was detected using a cell counter, and the cell viability at 0h was calculated; after determining the number of cells, the cell viability was calculated according to 1*10 7 / ml, premixed with the cell preservation solution of Examples 1-4 and Comparative Examples 1-4; the cell activities were counted and detected at 24h, 48h, 72h, 96h, and 120h, and the cell viability was calculated; Table 4 Human K562 cell survival rate
[0025] The experimental results show that: in the cell preservation solution of Example 4 at 2-8°C for 120 hours, the activity of K562 cells is still maintained above 92%.
[0026] The above data show that the cell preservation effect of the formula containing L-ascorbic acid-2-phosphate magnesium salt in Examples 1-4 is better than that of the formula containing vitamin C.
[0027] Example 8 Cell proliferation ability detection in cell preservation solution Detection of proliferation ability of human umbilical cord mesenchymal stem cells The human umbilical cord mesenchymal stem cells within 120 hours of storage in the cell preservation solution of Example 4 were collected and centrifuged, and the cells were resuspended in a complete medium to a culture bottle, placed in a CO2 incubator, cultured to P4, digested with trypsin, and centrifuged to collect the cells; the collected cells were resuspended in a serum-containing medium, counted with a cell counter, and diluted to a single cell suspension of 5x10^3~5x10^4 / ml. The cell suspension was inoculated in a 96-well plate, 100 μL per well, and the culture plate was placed in an incubator for pre-culture for about 24 hours (37°C, 5% CO2).
[0028] Add 10 μL CCK-8 solution to each well, place the culture plate in an incubator and incubate for 1-4 hours. Measure the absorbance (OD) at 450 nm with an ELISA reader. This experiment tested two time points, 24 hours and 48 hours.
[0029] NK cell proliferation ability detection The NK cells within 120 hours of storage in the cell preservation solution of Example 4 were collected and centrifuged, and the cells were resuspended in a complete medium to a culture flask / bag, placed in a CO2 incubator for culture, and the cells in the logarithmic growth phase were collected by centrifugation. After the collected cells were resuspended in a serum-containing medium, they were counted with a cell counter and diluted to a single cell suspension of 5x10^3~5x10^4 / ml. The cell suspension was inoculated in a 96-well plate, 100 μL per well, and the culture plate was placed in an incubator for pre-culture for about 24 hours (37°C, 5% CO2).
[0030] Add 10 μL CCK-8 solution to each well, place the culture plate in an incubator and incubate for 1-4 hours. Measure the absorbance (OD) at 450 nm with an ELISA reader. This experiment tested two time points, 24 hours and 48 hours.
[0031] K562 cell proliferation assay K562 cells within 120 hours of storage in the cell preservation solution of Example 4 were collected and centrifuged, and the cells were resuspended in a culture flask with complete culture medium and placed in a CO2 incubator for culture. Cells in the logarithmic growth phase were collected by centrifugation. The collected cells were resuspended in serum-containing culture medium, counted with a cell counter, and diluted to a single cell suspension of 5x10^3~5x10^4 / ml. The cell suspension was inoculated in a 96-well plate, 100 μL per well, and the culture plate was placed in an incubator for pre-culture for about 24 hours (37°C, 5% CO2).
[0032] Add 10 μL CCK-8 solution to each well, place the culture plate in an incubator and incubate for 1-4 hours. Measure the absorbance (OD) at 450 nm with an ELISA reader. This experiment tested two time points, 24 hours and 48 hours.
[0033] The results of the proliferation capacity assays of NK cells, human umbilical cord mesenchymal stem cells, and K562 cells are shown in Figure 1 The results showed that NK cells, human umbilical cord mesenchymal cells and K562 cells stored at 2-8℃ for 120h still had a high cell proliferation ability.
[0034] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A cell cryopreservation solution, characterized in that: The invention uses water as solvent and comprises sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid-2-phosphate magnesium salt, trehalose and hydrocortisone.
2. The cell cryopreservation solution according to claim 1, characterized in that The mass concentrations of the components are: sodium chloride 7.5-8.5 g / L, disodium hydrogen phosphate 1.3-1.5 g / L, sodium dihydrogen phosphate 480-500 mg / L, L-ascorbic acid-2-phosphate magnesium salt 64-128 mg / L, trehalose 50-100 g / L and hydrocortisone 350-520 μg / L.
3. The cell cryopreservation solution according to claim 2, characterized in that The mass concentrations of the components are: sodium chloride 8.0 g / L, disodium hydrogen phosphate 1.43 g / L, sodium dihydrogen phosphate 500 mg / L, L-ascorbic acid-2-phosphate magnesium salt 128 mg / L, trehalose 100 g / L and hydrocortisone 370 μg / L.
4. The cell cryopreservation solution according to any one of claims 1 to 3, characterized in that: The pH value of the cell preservation solution is between 6.8-7.
2.
5. The cell cryopreservation solution according to any one of claims 1 to 3, characterized in that: Endotoxin in cell preservation medium is less than 0.5EU / ml.
6. A method for preparing a cell cryopreservation solution, characterized in that: Weigh sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, trehalose, L-ascorbic acid-2-phosphate magnesium salt, and hydrocortisone as needed, then add pure water to 1 L, stir evenly, and collect the solution for filtration and sterilization; In the cell cryopreservation solution, the mass concentrations of the components are: sodium chloride 7.5-8.5 g / L, disodium hydrogen phosphate 1.3-1.5 g / L, sodium dihydrogen phosphate 480-500 mg / L, L-ascorbic acid-2-phosphate magnesium salt 64-128 mg / L, trehalose 50-100 g / L and hydrocortisone 350-520 μg / L.
7. Use of the cell cryopreservation solution according to claims 1-6 in the preservation of human umbilical cord mesenchymal stem cells.
8. Use of the cell cryopreservation solution as described in claims 1-6 in the preservation of NK cells.
9. Use of the cell cryopreservation solution according to claims 1 to 6 in the preservation of K562 cells.
